课件：帕金森病诊断进展.ppt

* Slide 43: Imaging in the Brain: Molecular Targets of Radioligands The cell on the left of the image is a dopamine cell. The dopamine transporter proteins are indicated in green. When [123I]?-CIT binds to the dopamine transporter protein, the dopaminergic neuron becomes radioactively labeled by the [123I] molecule on [123I]?-CIT.1 SPECT imaging is used to measure the distribution of dopaminergic neurons labeled with [123I]?-CIT.1 Dopaminergic neurons in the substantia nigra are of particular interest, since it is these cells that degenerate in Parkinson’s disease.2 SPECT imaging can quantify the number of functioning dopaminergic neurons in the substantia nigra by measuring the intensity of radioactive labeling with [123I]?-CIT.3 As dopaminergic neuronal function is lost during the progression of Parkinson’s disease, the intensity of radioactive labeling with [123I]?-CIT decreases.2,4 References: 1. Marek K, Seibyl J. A molecular map for degeneration. Science. 2000;279:409-411. 2. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Nat Acad Sci USA. 1993;90:11965-11969. 3. Seibyl JP, Scanley E, Krystal JH, et al. Neuroimaging methodologies. In: Charney DS, Nestler EJ, Bunney BS, eds. Neurobiology of Mental Illness. New York, NY: Oxford University Press; 1999:170-189. 4. Booij J, Tissingh G, Winogrodzka A, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur J Nucl Med. 1997;24:68-71. * Slide 45: Functional Imaging: Healthy Controls vs Parkinson’s Disease Here are two SPECT images. The first represents a healthy control subject with symmetrical striatal activity. The second image shows a subject with Parkinson’s disease with asymmetric reduction in striatal activity at Hoehn-Yahr Stage 1. This patient may or may not have been receiving dopaminergic therapy. The images dep